Equities

ADC Therapeutics SA

ADCT:NYQ

ADC Therapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.33
  • Today's Change0.12 / 3.74%
  • Shares traded1.89m
  • 1 Year change+333.59%
  • Beta1.5837
Data delayed at least 15 minutes, as of Sep 20 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments279326467
Total Receivables, Net257331
Total Inventory161211
Prepaid expenses162315
Other current assets, total----1.56
Total current assets336435525
Property, plant & equipment, net161011
Goodwill, net------
Intangibles, net----14
Long term investments1.657.6141
Note receivable - long term------
Other long term assets0.710.900.69
Total assets355491618
LIABILITIES
Accounts payable161212
Accrued expenses395316
Notes payable/short-term debt000
Current portion long-term debt/capital leases----7.60
Other current liabilities, total131738
Total current liabilities688274
Total long term debt416322313
Total debt416322320
Deferred income tax------
Minority interest------
Other liabilities, total197.4065
Total liabilities503411452
SHAREHOLDERS EQUITY
Common stock7.317.316.45
Additional paid-in capital1,1811,166982
Retained earnings (accumulated deficit)(1335)(1095)(822)
Treasury stock - common(0.54)(0.68)(0.13)
Unrealized gain (loss)------
Other equity, total(0.09)1.820.18
Total equity(148)79166
Total liabilities & shareholders' equity355491618
Total common shares outstanding828177
Treasury shares - common primary issue6.758.401.46
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.